CSIMarket Company Name, Ticker, Industry, else..
 
Summit Therapeutics Inc   (SMMT)
Other Ticker:  
 
 
Price: $1.9500 $-0.02 -1.015%
Day's High: $2.075 Week Perf: 0.00
Day's Low: $ 1.94 30 Day Perf: 1.3 %
Volume (M): 814 52 Wk High: $ 5.78
Volume (M$): $ 1,588 52 Wk Avg: $2.21
Open: $1.99 52 Wk Low: $0.66



 Market Capitalization (Millions $) 1,361
 Shares Outstanding (Millions) 698
 Employees 70
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -598
 Cash Flow (TTM) (Millions $) -98
 Capital Exp. (TTM) (Millions $) 0

Summit Therapeutics Inc
Summit Therapeutics Inc is a biopharmaceutical company founded in 2003 and based in Cambridge, England, with additional offices in Oxford, UK, and Cambridge, Massachusetts, USA. It specializes in developing innovative therapies for rare and infectious diseases.

Summit's mission is to discover, develop and commercialize novel medicines that target some of the most challenging diseases in the world. The company has a particular focus on developing drugs with macrocyclic chemistry, which can be used to create highly specific and potent drugs that are efficient in treating specific diseases.

One of Summit's flagship products is Ridinilazole, an antibiotic drug that is being developed to treat Clostridioides difficile (CDI), a debilitating and challenging infection that affects millions of people worldwide. CDI is responsible for several deaths each year and is a major public health concern.

Ridinilazole has been shown to be more effective than the current standard of care, Vancomycin, and has fewer side effects. In clinical trials, the drug has demonstrated a higher cure rate and a lower rate of recurrence than Vancomycin.

Summit also has a partnership with Cyclica, a biotech company specializing in AI-driven drug discovery. The collaboration aims to develop macrocycle-derived drug candidates using Cyclica's Ligand Express platform to analyze and predict the binding affinity of large and complex molecules.

Summit's portfolio includes a pipeline of products in various stages of development, targeting conditions such as: Duchenne muscular dystrophy, Charcot-Marie-Tooth disease, Rett syndrome, and others. The company's research is supported by a team of experienced scientists and industry leaders, who have a proven track record of drug discovery and development.

In addition, the company works closely with international regulatory authorities, agencies and partners to advance its programs and ensure that they meet the highest standards of safety and efficacy.

Summit Therapeutics Inc is traded on the NASDAQ exchange under the symbol SMMT.


   Company Address: 2882 Sand Hill Road, Suite 106 Menlo Park 94025 CA
   Company Phone Number: 460-8308   Stock Exchange / Ticker: NASDAQ SMMT
   SMMT is expected to report next financial results on December 20, 2023.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Evofem Biosciences Inc

Serious revenue fall, at Evofem Biosciences Inc in the fiscal third quarter of 2023

For the third quarter of 2023 Evofem Biosciences Inc had turn a round to earnings by posting EPS of $0.10 per share compare to $-0.04 a year prior and net profit per share turned positive from $-5.43 per share from the preceding financial reporting period. The revenue declined widely by -19.761 % to $5.11 million from $6.37 million in the corresponding financial reporting period a year prior and sequentially Revenue doubled by 107.974 % from $2.46 million.

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc. Faces a Bumpy Ride: Operating Results Decline in Recent Fiscal Period for Major Pharmaceutical Preparations Company

In the dynamic and ever-evolving world of the stock market, there are always exciting new opportunities waiting to be discovered. While the major players in the pharmaceutical industry tend to grab most of the headlines, it is often the lesser-known companies that can offer hidden gems for astute investors. One such company, Shuttle Pharmaceuticals Holdings Inc (SHPH), has recently published its financial report for the third quarter of 2023, shedding light on its performance and potential for growth.
Despite reporting an operating loss of $-1.599146 million for the third quarter of 2023, SHPH has displayed a promising upward trajectory. Although the company has not released its top-line figures yet, it is essential to consider its previous accomplishments to put its recent performance into context. In the third quarter of 2022, SHPH recorded an operating loss of $-0.821468 million, indicating significant progress within just one year.
Cingulate Inc

The company declared operating shortfall in the third quarter of 2023

Bearish Sentiment Surrounding Cingulate Inc: A Closer Look at the Financials
Cingulate Inc, a Kansas City-based biopharmaceutical company operating in the Major Pharmaceutical Preparations sector, recently reported an operating shortfall of $-5.749674 million for the third quarter of 2023. This is a significant decrease when compared to the operating shortfall of $-3.968362 million reported in the same quarter of the previous year.
This decline in financial performance is a cause for concern. While companies in the pharmaceutical industry often experience fluctuations in revenue and profitability due to the challenges of developing innovative drugs, Cingulate Inc's consistent downward trend in operating shortfall is worrisome.
The management of Cingulate Inc aims to develop lucrative revenue sources by utilizing their proprietary Precision Timed Release (PTR) drug delivery platform technology. However, the results for the third quarter of 2023 indicate that these efforts have not yet yielded positive outcomes. The operating shortfall soared to $-5.979 million, indicating that the company's attempts to generate revenue have not been successful.
Harrow Inc

Harrow Inc Achieves Remarkable 49.84% Top-line Surge during Exceptional Q3 2023 Earnings Season



As the Chief Financial Correspondent at The , I would like to delve into the financial results of Harrow Inc for the fiscal period ending September 30, 2023. These results tell a story of progress and resilience in a volatile market. Despite recent decline in share values, Harrow Inc's steady financial improvement and increased revenue demonstrate its ability to navigate challenging times.
Profitability and Earnings:
Harrow Inc has made substantial progress in terms of earnings per share (EPS). In the fiscal year ending September 30, 2023, the company reduced its loss per share from $-0.24 to $-0.13. This represents a significant improvement in profitability, reflecting the company's strong management and strategic decisions.
Renovorx Inc

Renovorx Inc Witnesses Decline in Q3 2023 Financial Performance, Sets Path for Recovery



As the earnings season progresses, financial results of various companies are being unveiled. One notable player in the Major Pharmaceutical Preparations sector, Renovorx Inc, recently disclosed its operating loss for the most recent fiscal period ending September 30, 2023. While the figures may seem concerning at first glance, a closer look reveals some interesting developments that could shape the company's future trajectory.
Operating Loss Reduction:
Renovorx Inc reported an operating loss of $-2.983 million for the third quarter of 2023. However, comparing this figure with the same period in 2022, we see a positive trend. In the third quarter of 2022, the operating loss was $-2.161 million, indicating a reduction in losses year-over-year. This demonstrates the company's efforts to streamline operations and improve efficiency, which is essential for its long-term viability.





 




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com